Tesamorelin 10 mg

Tesamorelin 10mg peptide is a synthetic analogue of growth hormone–releasing hormone (GHRH) studied for its ability to stimulate endogenous pulsatile growth hormone secretion through physiological GHRH receptor signaling pathways. In laboratory settings, Tesamorelin 10mg peptide is used to investigate pituitary-mediated growth hormone release, downstream insulin-like growth factor-1 (IGF-1) responses, and the relationship between GHRH receptor activation and broader metabolic regulation.

Research interest in Tesamorelin 10mg peptide centers on its effects on visceral adiposity, growth hormone pulsatility, and endocrine-metabolic signaling. Published studies have shown that tesamorelin increases endogenous GH pulsatility and raises IGF-1 in controlled research settings, supporting its use as a mechanistic tool for examining how GHRH analogue signaling influences body-composition and metabolic endpoints (Stanley et al., 2011 — Journal of Clinical Endocrinology & Metabolism).

Beyond adipose biology, Tesamorelin 10mg peptide has demonstrated relevance in liver-focused metabolic research. Clinical and translational work has associated tesamorelin with reductions in liver fat and attenuation of fibrosis progression in HIV-associated NAFLD, while transcriptomic analyses reported effects on pathways related to oxidative phosphorylation, inflammation, and tissue repair. These findings position tesamorelin as a broader metabolic research compound in studies of endocrine signaling, hepatic metabolism, and visceral fat regulation (Stanley et al., 2019 — Lancet HIV; Fourman et al., 2020 — JCI Insight).

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.